Endogenous IL-17 contributes to reduced tumor growth and metastasis
AUTOR(ES)
Kryczek, Ilona
FONTE
American Society of Hematology
RESUMO
It has been reported that ectopically expressed interleukin-17 (IL-17) in tumor cells suppresses tumor progression through enhanced antitumor immunity in immune competent mice or promote tumor progression through an increase in inflammatory angiogenesis in immune-deficient mice. The role of endogenous IL-17 in tumor immunity remains undefined. Here we showed that tumor growth and lung metastasis were enhanced in IL-17–deficient mice, associated with decreased interferon-γ+ natural killer cells and tumor specific interferon-γ+ T cells in the tumor draining lymph nodes and tumors. Together with the published data showing that in vitro transforming growth factor-β and IL-6–polarized Th17 cells induce tumor regression, our work supports the notion that endogenous IL-17 or/and Th17 cells may play a protective role in tumor immunity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2714210Documentos Relacionados
- IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis
- Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family
- Avaliação da participação de células produtoras de IL-17 (TH17) na paracoccidioidomicose humana : efeito do tratamento com IL-17 e IL-23 sobre a atividade fungicida e capacidade migratória de neutrófilos
- Retinal astrocytes respond to IL-17 differently than retinal pigment epithelial cells
- IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion
